secwatch.observer — SEC 8-K summary
======================================

Issuer:     OCULAR THERAPEUTIX, INC (OCUL)
CIK:        0001393434
Form:       8-K
Filed at:   2022-11-07T23:59:59+00:00
Accession:  0001104659-22-115406
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocular Therapeutix Q3 DEXTENZA revenue flat at $11.9M; net loss $24.2M; revises 2022 guidance to $48-52M
--------------------------------------------------------------------------------

- DEXTENZA net product revenue $11.9M in Q3 2022, flat YoY and down ~2% sequentially; 2022 guidance revised to $48-52M (10-20% growth).
- Net loss $24.2M ($0.31/share) vs net income $2.7M ($0.03/share) in Q3 2021; includes $1.1M non-cash derivative liability adjustment.
- OTX-TKI Phase 1 wet AMD interim: 80% rescue-free at 6 months, 73% at 7 months; Phase 2/3 planned for Q3 2023.
- Phase 1 trial for diabetic retinopathy expected to start Q1 2023; OTX-TIC Phase 2 enrollment ongoing, topline data Q4 2023.
- Cash and equivalents $121.0M as of Sep 30, 2022; sufficient to fund operations through 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1393434/000110465922115406/0001104659-22-115406-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1393434/000110465922115406/tm2229787d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-115406

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer